Publication: 2085

Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer—CALGB 40302 (Alliance)
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 32 (35) 3959-3966
Year:
2014
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
4
Parents:
444  
Children:
None
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, CA33601, CA77597, CA11789, CA77406, CA16359, CA47577, CA35113, CA32291, CA29165, N01 CA032102, CA41287, CA03927, U10 CA031946, U10 CA033601, CA59518, U10 CA180821, CA45389, CA45808, N01 CA046441, CA86726, CA16450, CA77440, CA45564, U10 CA032102, CA74811, U10 CA180882, CA21060, U10 CA046441, CA47559, CA47642, CA45418, U10 CA180888, CA31983, CA31946  
Corr. Author:
 
Authors:
                     
Networks:
 
Study
CALGB-40302
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Bc6, Bc7, ORIGINAL REPORTS, Breast Cancer